PMID- 37437408
OWN - NLM
STAT- MEDLINE
DCOM- 20230804
LR  - 20230804
IS  - 1532-2688 (Electronic)
IS  - 1059-1311 (Linking)
VI  - 110
DP  - 2023 Aug
TI  - Efficacy and safety of perampanel monotherapy in patients with focal-onset 
      seizures:A real-world experience in eastern China.
PG  - 231-237
LID - S1059-1311(23)00182-6 [pii]
LID - 10.1016/j.seizure.2023.06.024 [doi]
AB  - OBJECTIVE: To assess the effectiveness and tolerability of perampanel (PER) 
      monotherapy in real-world practice for the treatment of focal-onset seizures 
      (FOS) in eastern China. METHOD: This is a single-center, retrospective study of 
      patients with FOS, aged >/= 4 years, who had been prescribed PER as monotherapy. 
      Outcomes included retention, seizure-free, and responder rates at 3, 6 and 
      12 months and adverse events (AEs) throughout the follow-up period. The efficacy 
      and AEs of PER monotherapy in patients with aged < 14 years old and >/= 14 years 
      old were also compared. RESULTS: Sixty-seven patients with FOS who received PER 
      monotherapy and completed a one-year follow-up were included in the analysis. The 
      median maintenance dose was 4 mg. Modified intent-to-treat analysis demonstrated 
      that the retention rates of PER monotherapy at follow-up of 3, 6 and 12months 
      were 75%, 70% and 63%, respectively. At the same points, seizure-free rates of 
      PER monotherapy were 69%, 63% and 52%, and responder rates were 69%, 66% and 61%, 
      respectively. Patients with sleep-related seizures had higher seizure-free rates 
      at 12 months of follow-up. No significant difference in seizure-free and 
      responder rates was found between the aged < 14 years old and the aged >/= 14 years 
      old. Twenty-one patients (31.3%) had AEs and five patients discontinued using PER 
      because of intolerant AEs. Common AEs were dizziness, irritability and 
      somnolence. The AEs rate in patients < 14 years was 17.9%, significantly lower 
      than patients >/= 14 years. CONCLUSIONS: Our findings revealed the real-world data 
      of patients in eastern China with FOS using PER as monotherapy. Patients had good 
      retention, seizure-free and responder rates, and relatively low AEs rate at a low 
      dose of PER treatment.
CI  - Copyright (c) 2023 British Epilepsy Association. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Xu, Sha
AU  - Xu S
AD  - Department of Neurology, Epilepsy Center, the Second Affiliated Hospital of 
      Zhejiang University School of Medicine, Hangzhou, China.
FAU - Xu, Zheng-Yan-Ran
AU  - Xu ZY
AD  - Department of Neurology, Epilepsy Center, the Second Affiliated Hospital of 
      Zhejiang University School of Medicine, Hangzhou, China.
FAU - Zheng, Yuanyuan
AU  - Zheng Y
AD  - Department of Neurology, Epilepsy Center, the Second Affiliated Hospital of 
      Zhejiang University School of Medicine, Hangzhou, China.
FAU - Miao, Pu
AU  - Miao P
AD  - Department of Pediatrics, the Second Affiliated Hospital of Zhejiang University 
      School of Medicine, Hangzhou, China.
FAU - Feng, Jianhua
AU  - Feng J
AD  - Department of Pediatrics, the Second Affiliated Hospital of Zhejiang University 
      School of Medicine, Hangzhou, China.
FAU - Guo, Yi
AU  - Guo Y
AD  - Department of Neurology, Epilepsy Center, the Second Affiliated Hospital of 
      Zhejiang University School of Medicine, Hangzhou, China; Department of General 
      Practice and International Medicine, the Second Affiliated Hospital of Zhejiang 
      University School of Medicine, Hangzhou, China; Key Laboratory of Medical 
      Molecular Imaging of Zhejiang Province, Hangzhou, China. Electronic address: 
      yiguo@zju.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20230706
PL  - England
TA  - Seizure
JT  - Seizure
JID - 9306979
RN  - H821664NPK (perampanel)
RN  - 0 (Anticonvulsants)
RN  - 0 (Pyridones)
SB  - IM
MH  - Humans
MH  - Adolescent
MH  - *Anticonvulsants/adverse effects
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - *Seizures/drug therapy/chemically induced
MH  - Pyridones/adverse effects
MH  - China
MH  - Drug Therapy, Combination
OTO - NOTNLM
OT  - Efficacy
OT  - Epilepsy
OT  - Monotherapy
OT  - Perampanel
OT  - Real-world
OT  - Safety
COIS- Declaration of Competing Interest The authors declare no conflict of interest.
EDAT- 2023/07/13 01:06
MHDA- 2023/08/04 06:43
CRDT- 2023/07/12 18:04
PHST- 2023/04/22 00:00 [received]
PHST- 2023/06/07 00:00 [revised]
PHST- 2023/06/30 00:00 [accepted]
PHST- 2023/08/04 06:43 [medline]
PHST- 2023/07/13 01:06 [pubmed]
PHST- 2023/07/12 18:04 [entrez]
AID - S1059-1311(23)00182-6 [pii]
AID - 10.1016/j.seizure.2023.06.024 [doi]
PST - ppublish
SO  - Seizure. 2023 Aug;110:231-237. doi: 10.1016/j.seizure.2023.06.024. Epub 2023 Jul 
      6.